News

The results from this study confirmed CTP-656’s superior pharmacokinetic profile to Kalydeco as was previously reported from Concert’s single ascending dose trial, which demonstrated favorable pharmacokinetic properties with

The LAVOLTA I-II studies were identical, double-blind, randomised, multicentre, placebo-controlled studies that evaluated the efficacy and safety of lebrikizumab in people with severe asthma. LAVOLTA I met its

RespireRx plans to start a phase 2A clinical trial by the end of this month to confirm the ability of CX1739 to antagonize the respiratory depressant effects of

The trial of 10 mg/kg tremelimumab monotherapy in second or third-line treatment of unresectable malignant mesothelioma failed to hit its primary target. AstraZeneca senior vice president, head of

Lice are a nuisance and causes embarrassment for many, however carry no serious harm. While lice have built a resistance for over-the-counter products there are several prescription products

NS2 is an aldehyde-binding small molecule based on a platform technology that centers on trapping aldehydes, which are toxic and pro-inflammatory mediators of several diseases. It lowers aldehyde

Menarini AP will receive exclusive licensing rights from Mitsubishi Tanabe Pharma Corporation to market Avanafil in China, Hong Kong, Macao, Taiwan, Indonesia, Malaysia, Philippines, Singapore, Thailand, Vietnam. Menarini

A ground-breaking project announced by the British Prime Minister David Cameron in 2012, the 100,000 Genomes Project is sequencing 100,000 whole genomes from 70,000 National Health Service (NHS)

Published in the February 2016 edition of Clinical Trials: Journal of the Society for Clinical Trials, the analysis identifies different factors, such as therapeutic area, patient recruitment, administrative